WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report

Anticancer Res. 2011 Jul;31(7):2441-5.

Abstract

We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.

Case report: Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Biomarkers, Tumor / blood
  • CA-125 Antigen / blood
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / therapeutic use*
  • Carboplatin / administration & dosage
  • Clinical Trials, Phase II as Topic
  • Combined Modality Therapy
  • Cystadenocarcinoma, Serous / drug therapy
  • Cystadenocarcinoma, Serous / secondary*
  • Cystadenocarcinoma, Serous / surgery
  • Cystadenocarcinoma, Serous / therapy
  • Docetaxel
  • Female
  • HLA-A Antigens / administration & dosage
  • HLA-A Antigens / immunology
  • HLA-A24 Antigen
  • Humans
  • Immunotherapy, Active*
  • Membrane Proteins / blood
  • Middle Aged
  • Omentum / pathology
  • Omentum / surgery
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / surgery
  • Ovarian Neoplasms / therapy*
  • Paclitaxel / administration & dosage
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / immunology
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / secondary*
  • Peritoneal Neoplasms / surgery
  • Peritoneal Neoplasms / therapy
  • Taxoids / administration & dosage
  • Tumor Burden
  • Vaccines, Subunit / administration & dosage
  • Vaccines, Subunit / therapeutic use
  • WT1 Proteins / administration & dosage
  • WT1 Proteins / immunology*

Substances

  • Adjuvants, Immunologic
  • Biomarkers, Tumor
  • CA-125 Antigen
  • Cancer Vaccines
  • HLA-A Antigens
  • HLA-A*24:02 antigen
  • HLA-A24 Antigen
  • MUC16 protein, human
  • Membrane Proteins
  • Peptide Fragments
  • Taxoids
  • Vaccines, Subunit
  • WT1 Proteins
  • Docetaxel
  • Carboplatin
  • Paclitaxel